Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), beta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | polymerase (DNA directed), beta | 335 aa | 303 aa | 32.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | epidermal growth factor receptor | 0.0553 | 0.5694 | 0.4996 |
Leishmania major | 0.0932 | 1 | 1 | |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0365 | 0.356 | 0.356 |
Brugia malayi | Protein kinase domain containing protein | 0.0174 | 0.1394 | 0.0379 |
Toxoplasma gondii | fructose-bisphospatase I | 0.0346 | 0.3353 | 0.3295 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0173 | 0.1378 | 0.1378 |
Mycobacterium ulcerans | hypothetical protein | 0.0192 | 0.1599 | 0.5 |
Toxoplasma gondii | sedoheptulose-1,7-bisphosphatase | 0.0346 | 0.3353 | 0.3295 |
Echinococcus multilocularis | 0.0248 | 0.2238 | 0.0981 | |
Leishmania major | mitochondrial DNA polymerase beta | 0.0365 | 0.356 | 0.2531 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 0.356 | 0.356 |
Echinococcus granulosus | epidermal growth factor receptor | 0.0349 | 0.3378 | 0.2306 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0553 | 0.5694 | 0.4996 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0349 | 0.3378 | 0.2306 |
Echinococcus granulosus | melanoma receptor tyrosine protein kinase | 0.0349 | 0.3378 | 0.2306 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0062 | 0.0127 | 0.0127 |
Schistosoma mansoni | tyrosine kinase | 0.0346 | 0.335 | 0.2273 |
Schistosoma mansoni | tyrosine kinase | 0.0346 | 0.335 | 0.2273 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0346 | 0.3353 | 0.3353 |
Schistosoma mansoni | tyrosine kinase | 0.0349 | 0.3378 | 0.2306 |
Brugia malayi | Furin-like cysteine rich region family protein | 0.0553 | 0.5694 | 0.5186 |
Loa Loa (eye worm) | TK/INSR protein kinase | 0.0174 | 0.1394 | 0.0379 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0932 | 1 | 1 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0932 | 1 | 1 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0932 | 1 | 1 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0932 | 1 | 1 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0932 | 1 | 1 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0932 | 1 | 1 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0932 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0192 | 0.1599 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 0.356 | 0.356 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0173 | 0.1378 | 0.1378 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.8883 | 0.8702 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0932 | 1 | 1 |
Trypanosoma brucei | sedoheptulose-1,7-bisphosphatase | 0.0346 | 0.3353 | 0.3353 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.8883 | 0.8702 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0346 | 0.3353 | 0.3353 |
Schistosoma mansoni | tyrosine kinase | 0.0553 | 0.5694 | 0.4996 |
Schistosoma mansoni | tyrosine kinase | 0.0346 | 0.335 | 0.2273 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.8883 | 0.8702 |
Schistosoma mansoni | tyrosine kinase | 0.0349 | 0.3378 | 0.2306 |
Loa Loa (eye worm) | TK/EGFR protein kinase | 0.0553 | 0.5694 | 0.5186 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.1585 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.2589 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 2.8184 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.